5AM Ventures

RareCyte, Inc. is a life sciences company based in Seattle, Washington, founded in 2009. The company specializes in developing advanced platforms for liquid and tissue biopsy analysis, focusing on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in blood samples. RareCyte's AccuCyte system provides an open platform that facilitates the unbiased discovery and isolation of these rare cells, supporting various applications in cancer research, cardiovascular disease studies, and diagnostic development. The company offers a range of products, including sample preparation systems, staining kits, automated fluorescence microscopy instruments, and slide imaging systems. By enabling precision medicine approaches, RareCyte aims to provide new tools for medical professionals and researchers to address complex questions in the fields of cancer and other therapeutic areas.

Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.

Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain. The company aims to target pain at its source to provide effective, rapid-acting pain relief without the risk of addiction. Their lead program targets Nav1.8, a validated human pain target, leveraging internal ion channel expertise.

Adverum Biotechnologies is a clinical-stage company focused on developing gene therapies to treat ocular diseases. Its pipeline includes ADVM-022 for wet age-related macular degeneration, ADVM-043 for alpha-1 antitrypsin deficiency, and preclinical candidates for other indications.

Silence Therapeutics is a London-based biotechnology company that develops RNA therapeutics using short interfering RNA to trigger RNA interference and degrade disease-causing messenger RNA. It focuses on discovery, development, and delivery of siRNA medicines for hematology, cardiovascular disease, and other rare and metabolic conditions. The company has a proprietary mRNAi GOLD platform to create internal candidates and collaborates on out-licensed programs, including a strategic partnership with AstraZeneca to discover, develop, and commercialize siRNA therapies across cardiovascular, renal, metabolic, and respiratory indications, as well as a collaboration with Genomics England. Its product candidates include SLN124 for iron overload, SLN360 for cardiovascular disease associated with high lipoprotein, and SLN500 for complement-mediated diseases. Silence Therapeutics also pursues delivery systems for targeting multiple organs and cell types, supporting a pipeline across its three focus areas.

Tyra Biosciences is a biotechnology company focused on developing precision therapies for cancer. It uses its proprietary SNAP platform to create next-generation drug candidates that target acquired drug resistance, with an initial focus on the Fibroblast Growth Factor Receptor (FGFR) family.

Skye Bioscience is a preclinical pharmaceutical company focused on metabolic disorders, inflammation, fibrosis, and neurodegeneration through modulation of the cannabinoid receptor 1 (CB1). Based in San Diego, California, it develops proprietary molecules with assets aimed at obesity and glaucoma, including nimacimab, a peripheral CB1 receptor–modulating antibody in Phase 2 development, and SBI-100 Ophthalmic Emulsion, a CB1 agonist being developed for glaucoma.

GlycoEra is a biotechnology company focused on developing novel therapeutics by harnessing the power of glycan-mediated biology.

MapLight Therapeutics is focused on discovering and developing innovative therapies for brain disorders. The company utilizes a unique platform that integrates single-cell transcriptomics with optogenetics, enabling the identification of novel drug targets. By leveraging these advanced technologies, MapLight aims to create effective treatments tailored to address complex neurological conditions. Founded in 2018 and based in San Francisco, California, the company is committed to advancing the understanding and treatment of brain disorders through its cutting-edge research and development efforts.

Nvelop Therapeutics develops programmable delivery systems for in vivo gene editing and therapeutic cargo delivery. It combines epigenetic editing technologies with next-generation delivery methods to address unmet medical needs. The company focuses on genetic medicines designed to target cells and tissues within the body, aiming to treat severe genetic diseases by delivering gene-editing payloads to therapeutically relevant sites. Early efforts are aligned with enabling editing in cells and tissues that have been difficult to reach, with the objective of expanding the range of actionable genetic therapies. The company seeks to advance in vivo approaches that can improve precision and safety in delivering therapeutic cargo to patients.

Skye Bioscience is a preclinical pharmaceutical company focused on metabolic disorders, inflammation, fibrosis, and neurodegeneration through modulation of the cannabinoid receptor 1 (CB1). Based in San Diego, California, it develops proprietary molecules with assets aimed at obesity and glaucoma, including nimacimab, a peripheral CB1 receptor–modulating antibody in Phase 2 development, and SBI-100 Ophthalmic Emulsion, a CB1 agonist being developed for glaucoma.

Spruce Biosciences is a biopharmaceutical company focused on developing therapies for rare endocrine disorders. Its pipeline includes tildacerfont for classic congenital adrenal hyperplasia in adults and children, with ongoing clinical development, and Tralesinidase Alfa in its portfolio. The company collaborates with Eli Lilly to research, develop, and commercialize compounds. Founded in 2014, Spruce Biosciences is headquartered in Daly City, California, and aims to deliver meaningful therapies for patients with rare endocrine diseases.

Disc Medicine is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with severe hematologic disorders. Its pipeline includes therapies targeting erythropoietic porphyrias, Diamond-Blackfan Anemia, anemia of myelofibrosis and chronic kidney disease, as well as polycythemia vera.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for severe autoimmune diseases through targeted therapies. The company's lead candidate, DNTH103, is a monoclonal antibody designed to selectively inhibit a specific component of the immune system, offering potential advantages over existing complement therapies. This treatment aims to improve safety and efficacy for patients suffering from serious autoimmune and inflammatory conditions. Dianthus is committed to advancing its pipeline of next-generation complement therapeutics, supported by a team of experienced professionals in the biotech and pharmaceutical sectors. The company envisions that DNTH103 could be administered as a self-injection for certain patients, enhancing convenience and accessibility in treatment.

GlycoEra is a biotechnology company focused on developing novel therapeutics by harnessing the power of glycan-mediated biology.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, founded in 2009. The company specializes in developing advanced platforms for liquid and tissue biopsy analysis, focusing on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in blood samples. RareCyte's AccuCyte system provides an open platform that facilitates the unbiased discovery and isolation of these rare cells, supporting various applications in cancer research, cardiovascular disease studies, and diagnostic development. The company offers a range of products, including sample preparation systems, staining kits, automated fluorescence microscopy instruments, and slide imaging systems. By enabling precision medicine approaches, RareCyte aims to provide new tools for medical professionals and researchers to address complex questions in the fields of cancer and other therapeutic areas.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Founded in 2019, Enliven Therapeutics is a precision oncology company based in Boulder, Colorado. It focuses on developing small molecule therapies to extend and improve patient lives by targeting clinically validated biological targets with industry-leading chemistry.

Inipharm Inc. is a biopharmaceutical company established in 2018 and headquartered in Bellevue, Washington. The company specializes in discovering and developing therapies for severe liver diseases. Its research focuses on small-molecule drugs that target HSD17B13, a gene implicated in various liver conditions, including nonalcoholic steatohepatitis (NASH). By modulating the activity of HSD17B13, Inipharm aims to provide innovative treatments that can significantly reduce liver damage, inflammation, and fibrosis in affected patients.

Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.

Nido Biosciences is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing precision medicines and small-molecule therapeutics for severe neurological and neuromuscular diseases. It employs a functional genomics platform using human cell lines and tailored screens to identify therapeutic targets driven by human genetics, with the aim of addressing the underlying biology of disease and restoring healthy cell function through targeted interventions.

Vor Biopharma develops innovative cancer therapies focused on engineered hematopoietic stem cells (eHSCs). Its lead product candidate, VOR33, is designed to treat acute myeloid leukemia by generating healthy cells resistant to targeted immunotherapies. Incorporated in 2015, the company is based in Cambridge, Massachusetts.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, founded in 2009. The company specializes in developing advanced platforms for liquid and tissue biopsy analysis, focusing on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in blood samples. RareCyte's AccuCyte system provides an open platform that facilitates the unbiased discovery and isolation of these rare cells, supporting various applications in cancer research, cardiovascular disease studies, and diagnostic development. The company offers a range of products, including sample preparation systems, staining kits, automated fluorescence microscopy instruments, and slide imaging systems. By enabling precision medicine approaches, RareCyte aims to provide new tools for medical professionals and researchers to address complex questions in the fields of cancer and other therapeutic areas.

Nido Biosciences is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing precision medicines and small-molecule therapeutics for severe neurological and neuromuscular diseases. It employs a functional genomics platform using human cell lines and tailored screens to identify therapeutic targets driven by human genetics, with the aim of addressing the underlying biology of disease and restoring healthy cell function through targeted interventions.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company focuses on developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By creating enzyme inhibitors designed to disrupt these pathways, Cleave Therapeutics aims to address both oncological and neurodegenerative diseases. Through its innovative approach to drug discovery, the company seeks to provide effective therapeutic solutions that enhance patient outcomes in the fight against cancer.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of innovative treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its clinical candidates toward marketing approval, CinCor seeks to provide effective solutions for patients suffering from these conditions.

Vor Biopharma develops innovative cancer therapies focused on engineered hematopoietic stem cells (eHSCs). Its lead product candidate, VOR33, is designed to treat acute myeloid leukemia by generating healthy cells resistant to targeted immunotherapies. Incorporated in 2015, the company is based in Cambridge, Massachusetts.

Pear Therapeutics, Inc. is a Boston-based commercial-stage healthcare company specializing in software-based digital therapeutics, also known as Prescription Digital Therapeutics (PDTs). Founded in 2013, the company develops clinically validated software solutions designed to treat a range of behavioral health disorders, including addiction, anxiety, depression, and chronic insomnia. Its suite of products includes mobile digital therapies that reward patients for engagement, and specific tools like reSET and reSET-O, aimed at treating substance use disorders. The company also offers Somryst, which provides neurobehavioral interventions for insomnia, and operates PearConnect, a patient services center that connects patients with advocates and resources, ensuring support throughout their treatment journey. Pear Therapeutics aims to enhance treatment outcomes by integrating digital therapies with pharmaceuticals and providing comprehensive support for patients, clinicians, and payors.

Cabaletta Bio is a clinical-stage biotechnology company focused on developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology, chimeric autoantibody receptor (CAAR) T cells, selectively targets and eliminates disease-causing B cells while sparing healthy ones. Cabaletta's lead product candidate, DSG3-CAART, is in Phase I clinical trials for treating mucosal pemphigus vulgaris.

Founded in 2019, Enliven Therapeutics is a precision oncology company based in Boulder, Colorado. It focuses on developing small molecule therapies to extend and improve patient lives by targeting clinically validated biological targets with industry-leading chemistry.

Entrada Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on treating diseases through the intracellular delivery of biologics. Founded in 2016, the company has developed innovative technologies that facilitate the efficient delivery of proteins, peptides, and nucleic acids, targeting intracellular sites that have traditionally been difficult to access. Entrada's approach includes Intracellular Enzyme Replacement Therapy (IC-ERT) and Endosomal Escape Vehicle (EEV) therapeutics, which aim to improve the therapeutic index by enabling the delivery of a wide range of therapeutics across various organs and tissues. The company's pipeline addresses conditions related to neuromuscular diseases and expands into additional therapeutic areas, positioning Entrada at the forefront of advancing treatment options for patients with devastating illnesses.

Aprea Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, that specializes in developing cancer therapeutics aimed at reactivating the mutant p53 tumor suppressor protein. Its primary product candidate, APR-246, is a small molecule p53 reactivator currently undergoing late-stage clinical development for hematologic malignancies, particularly myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006, Aprea is focused on advancing innovative treatments that target critical mechanisms in cancer biology to improve patient outcomes.

Cabaletta Bio is a clinical-stage biotechnology company focused on developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology, chimeric autoantibody receptor (CAAR) T cells, selectively targets and eliminates disease-causing B cells while sparing healthy ones. Cabaletta's lead product candidate, DSG3-CAART, is in Phase I clinical trials for treating mucosal pemphigus vulgaris.

Nohla Therapeutics, Inc., established in 2015 and headquartered in Seattle, Washington, specializes in developing and manufacturing ex vivo expanded universal donor cellular therapies. The company's core technology enables the expansion of key cancer-fighting cells from umbilical cord blood, eliminating the need for HLA matching. Nohla offers programs such as Natural Killer (NK) cell therapy and Dilanubicel, a universal donor hematopoietic stem and progenitor cell product used for treating chemotherapy-induced neutropenia and other indications. Its products are manufactured and cryopreserved in advance, ensuring immediate availability for patient treatment.

Nohla Therapeutics, Inc., established in 2015 and headquartered in Seattle, Washington, specializes in developing and manufacturing ex vivo expanded universal donor cellular therapies. The company's core technology enables the expansion of key cancer-fighting cells from umbilical cord blood, eliminating the need for HLA matching. Nohla offers programs such as Natural Killer (NK) cell therapy and Dilanubicel, a universal donor hematopoietic stem and progenitor cell product used for treating chemotherapy-induced neutropenia and other indications. Its products are manufactured and cryopreserved in advance, ensuring immediate availability for patient treatment.

Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.

Rallybio is a clinical-stage biopharmaceutical company focused on developing therapies for severe and rare diseases. Its programs cover hematology, immuno-inflammation, maternal-fetal health and metabolic disorders, with a lead candidate aimed at preventing fetal and neonatal alloimmune thrombocytopenia, a life-threatening condition that can cause bleeding in fetuses and newborns. Founded in 2018 and based in New Haven, Connecticut, Rallybio develops therapies across antibodies, small molecules and engineered proteins to address unmet needs in rare diseases. Guided by experienced biopharma leadership, the company emphasizes translating biology into transformative therapies for underserved patients.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Crinetics Pharmaceuticals is a clinical-stage company focused on discovering, developing, and commercializing therapeutics targeting peptide hormone receptors for treating rare endocrine diseases and related cancers. Its lead product candidate, paltusotine, is an oral selective nonpeptide somatostatin receptor type 2 biased agonist in Phase I trials for acromegaly and neuroendocrine tumors.

Pear Therapeutics, Inc. is a Boston-based commercial-stage healthcare company specializing in software-based digital therapeutics, also known as Prescription Digital Therapeutics (PDTs). Founded in 2013, the company develops clinically validated software solutions designed to treat a range of behavioral health disorders, including addiction, anxiety, depression, and chronic insomnia. Its suite of products includes mobile digital therapies that reward patients for engagement, and specific tools like reSET and reSET-O, aimed at treating substance use disorders. The company also offers Somryst, which provides neurobehavioral interventions for insomnia, and operates PearConnect, a patient services center that connects patients with advocates and resources, ensuring support throughout their treatment journey. Pear Therapeutics aims to enhance treatment outcomes by integrating digital therapies with pharmaceuticals and providing comprehensive support for patients, clinicians, and payors.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, founded in 2009. The company specializes in developing advanced platforms for liquid and tissue biopsy analysis, focusing on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in blood samples. RareCyte's AccuCyte system provides an open platform that facilitates the unbiased discovery and isolation of these rare cells, supporting various applications in cancer research, cardiovascular disease studies, and diagnostic development. The company offers a range of products, including sample preparation systems, staining kits, automated fluorescence microscopy instruments, and slide imaging systems. By enabling precision medicine approaches, RareCyte aims to provide new tools for medical professionals and researchers to address complex questions in the fields of cancer and other therapeutic areas.

Nohla Therapeutics, Inc., established in 2015 and headquartered in Seattle, Washington, specializes in developing and manufacturing ex vivo expanded universal donor cellular therapies. The company's core technology enables the expansion of key cancer-fighting cells from umbilical cord blood, eliminating the need for HLA matching. Nohla offers programs such as Natural Killer (NK) cell therapy and Dilanubicel, a universal donor hematopoietic stem and progenitor cell product used for treating chemotherapy-induced neutropenia and other indications. Its products are manufactured and cryopreserved in advance, ensuring immediate availability for patient treatment.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company focuses on developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By creating enzyme inhibitors designed to disrupt these pathways, Cleave Therapeutics aims to address both oncological and neurodegenerative diseases. Through its innovative approach to drug discovery, the company seeks to provide effective therapeutic solutions that enhance patient outcomes in the fight against cancer.

Bioz is a cloud-based, AI-driven search and data-mining platform for life sciences that analyzes peer-reviewed literature, including full text and materials and methods sections, to identify reagents, instruments, equipment, and consumables. It provides relevancy-ranked results, research-relevant correlations, product ratings, and collaboration optimization, helping scientists quickly find, compare, and select the right products. By structuring data from the articles, Bioz accelerates experimentation and speeds drug discovery for researchers in academia and biopharma. Founded in 2013 and based in Palo Alto, Bioz aims to streamline procurement and enable faster scientific progress by turning complex literature into actionable product insights.

IDEAYA Biosciences is an oncology-focused biotechnology company dedicated to discovering targeted therapeutics for patient populations selected using molecular diagnostics. Its pipeline includes small molecule inhibitors targeting DNA damage and repair pathways, such as MAT2A, PARG, and Pol-theta, as well as immuno-oncology therapies targeting the tumor microenvironment.

Homology Medicines is a biotechnology company focused on developing genetic therapies for rare diseases. Its proprietary platform uses human hematopoietic stem cell-derived adeno-associated virus vectors to deliver treatments in vivo, targeting various tissues including the liver and central nervous system. The company's lead product candidate, HMI-102, is in clinical trials for treating phenylketonuria.

Aprea Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, that specializes in developing cancer therapeutics aimed at reactivating the mutant p53 tumor suppressor protein. Its primary product candidate, APR-246, is a small molecule p53 reactivator currently undergoing late-stage clinical development for hematologic malignancies, particularly myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006, Aprea is focused on advancing innovative treatments that target critical mechanisms in cancer biology to improve patient outcomes.

Pear Therapeutics, Inc. is a Boston-based commercial-stage healthcare company specializing in software-based digital therapeutics, also known as Prescription Digital Therapeutics (PDTs). Founded in 2013, the company develops clinically validated software solutions designed to treat a range of behavioral health disorders, including addiction, anxiety, depression, and chronic insomnia. Its suite of products includes mobile digital therapies that reward patients for engagement, and specific tools like reSET and reSET-O, aimed at treating substance use disorders. The company also offers Somryst, which provides neurobehavioral interventions for insomnia, and operates PearConnect, a patient services center that connects patients with advocates and resources, ensuring support throughout their treatment journey. Pear Therapeutics aims to enhance treatment outcomes by integrating digital therapies with pharmaceuticals and providing comprehensive support for patients, clinicians, and payors.

Crinetics Pharmaceuticals is a clinical-stage company focused on discovering, developing, and commercializing therapeutics targeting peptide hormone receptors for treating rare endocrine diseases and related cancers. Its lead product candidate, paltusotine, is an oral selective nonpeptide somatostatin receptor type 2 biased agonist in Phase I trials for acromegaly and neuroendocrine tumors.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Pulmatrix is a clinical-stage biopharmaceutical company developing inhaled therapies to address serious pulmonary diseases using its patented iSPERSE technology. Its pipeline focuses on Pulmazole, an inhaled anti-fungal for allergic bronchopulmonary aspergillosis, and PUR1800, a narrow spectrum kinase inhibitor for obstructive lung diseases like asthma and COPD.

Founded in 2013, Spyryx Biosciences is a biopharmaceutical company dedicated to developing inhaled peptide therapeutics for obstructive lung diseases. Its primary focus is on cystic fibrosis and chronic obstructive pulmonary disease (COPD). The company's innovative approach aims to address the root causes of these conditions by targeting mechanisms that regulate fluid in the lungs.

Pear Therapeutics, Inc. is a Boston-based commercial-stage healthcare company specializing in software-based digital therapeutics, also known as Prescription Digital Therapeutics (PDTs). Founded in 2013, the company develops clinically validated software solutions designed to treat a range of behavioral health disorders, including addiction, anxiety, depression, and chronic insomnia. Its suite of products includes mobile digital therapies that reward patients for engagement, and specific tools like reSET and reSET-O, aimed at treating substance use disorders. The company also offers Somryst, which provides neurobehavioral interventions for insomnia, and operates PearConnect, a patient services center that connects patients with advocates and resources, ensuring support throughout their treatment journey. Pear Therapeutics aims to enhance treatment outcomes by integrating digital therapies with pharmaceuticals and providing comprehensive support for patients, clinicians, and payors.

Cidara Therapeutics is a biotechnology company dedicated to developing novel anti-infectives. Its primary focus is rezafungin acetate, an antifungal for treating serious invasive fungal infections. Additionally, it advances the Cloudbreak platform to develop antiviral therapies using Fc-conjugates.

IDEAYA Biosciences is an oncology-focused biotechnology company dedicated to discovering targeted therapeutics for patient populations selected using molecular diagnostics. Its pipeline includes small molecule inhibitors targeting DNA damage and repair pathways, such as MAT2A, PARG, and Pol-theta, as well as immuno-oncology therapies targeting the tumor microenvironment.

Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

Cidara Therapeutics is a biotechnology company dedicated to developing novel anti-infectives. Its primary focus is rezafungin acetate, an antifungal for treating serious invasive fungal infections. Additionally, it advances the Cloudbreak platform to develop antiviral therapies using Fc-conjugates.

Bird Rock Bio, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, with a research facility in Shanghai, China. The company specializes in the discovery and development of novel biologic therapeutics aimed at addressing immune-inflammatory conditions, including rheumatoid arthritis, metabolic diseases, fibrosis, and nonalcoholic steatohepatitis. Bird Rock Bio's technology focuses on creating highly selective monoclonal antibodies targeting specific members of the G-protein coupled receptor (GPCR) family, a class of proteins critical for therapeutic efficacy. Its lead product, RYI-008, is a potent monoclonal antibody targeting IL-6, a cytokine linked to inflammation and cancer. The company is dedicated to meeting the medical needs of patients in China while also aiming for global impact. Bird Rock Bio has a growing pipeline of therapeutic antibodies developed through proprietary technologies that ensure specificity and effectiveness in treatment.

Igenica, Inc. is a biotherapeutic company based in Burlingame, California, that specializes in the discovery and development of antibodies and antibody-drug conjugates (ADCs) for cancer treatment. Founded in 2008, the company focuses on creating innovative immunotherapies and functional antibodies targeting tumors. Its product pipeline includes IGN523, a humanized monoclonal antibody for various hematologic and solid tumors; IGN786, an antibody-drug conjugate; and IGN381, an immune checkpoint target that enhances the tumor microenvironment. Igenica operates with a strategic oncology research agreement with MedImmune and is supported by a leadership team experienced in antibody drug discovery and clinical development. As of 2017, Igenica operates as a subsidiary of Pierre Fabre Medicament SA, positioning it to leverage additional resources and expertise in the biotherapeutics field.

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company dedicated to developing innovative treatments for cardiopulmonary diseases. Headquartered in Warren, New Jersey, the company focuses on its proprietary INOpulse platform, which delivers pulsatile nitric oxide, targeting various forms of pulmonary hypertension. Bellerophon is advancing multiple product candidates through clinical trials, including treatments for pulmonary hypertension associated with interstitial lung disease and chronic obstructive pulmonary disease, as well as other conditions such as sarcoidosis and chronic thromboembolic pulmonary hypertension. Additionally, Bellerophon is exploring a bioabsorbable cardiac matrix device aimed at preventing cardiac remodeling after myocardial infarction, currently undergoing a feasibility clinical trial in the European Union. Founded in 2009 and previously known as Ikaria Development LLC, Bellerophon Therapeutics aims to address significant unmet medical needs in the cardiopulmonary space.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

Novira Therapeutics is a clinical‑stage biopharmaceutical company that discovers and develops oral antiviral drugs targeting the capsid of hepatitis B virus and human immunodeficiency virus. Its pipeline focuses on first‑in‑class capsid inhibitors that can be used alone or with existing therapies, aiming to overcome limitations of current polymerase inhibitors and drug‑resistant HIV strains. The company was founded in 2006 as Molecmo Nanobiotechnologies and is headquartered in Doylestown, Pennsylvania. It has pursued partnerships and collaborations to advance its candidates toward clinical evaluation.

Achaogen, Inc. is a biopharmaceutical company based in South San Francisco, California, that specializes in the development and commercialization of antibacterial agents targeting multi-drug resistant (MDR) gram-negative infections. The company's primary focus is on plazomicin, which is intended for treating serious bacterial infections caused by MDR enterobacteriaceae, including carbapenem-resistant strains. Additionally, Achaogen is developing C-Scape, an orally-administered combination of clavulanate and ceftibuten aimed at addressing serious infections linked to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established collaborations with various organizations, including Thermo Fisher Scientific and Ionis Pharmaceuticals, to support its drug development efforts. The company was incorporated in 2002, but faced financial difficulties, leading to a Chapter 11 bankruptcy filing in 2019, which culminated in a liquidation plan approved in 2020. All of Achaogen's revenue has been derived from government contracts for research and development within the United States.

Flexion Therapeutics is a biopharmaceutical company dedicated to discovering, developing, and commercializing therapies for managing musculoskeletal conditions. Its flagship product, ZILRETTA, is an intra-articular injection used for knee osteoarthritis pain management in the United States.

Igenica, Inc. is a biotherapeutic company based in Burlingame, California, that specializes in the discovery and development of antibodies and antibody-drug conjugates (ADCs) for cancer treatment. Founded in 2008, the company focuses on creating innovative immunotherapies and functional antibodies targeting tumors. Its product pipeline includes IGN523, a humanized monoclonal antibody for various hematologic and solid tumors; IGN786, an antibody-drug conjugate; and IGN381, an immune checkpoint target that enhances the tumor microenvironment. Igenica operates with a strategic oncology research agreement with MedImmune and is supported by a leadership team experienced in antibody drug discovery and clinical development. As of 2017, Igenica operates as a subsidiary of Pierre Fabre Medicament SA, positioning it to leverage additional resources and expertise in the biotherapeutics field.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company focuses on developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By creating enzyme inhibitors designed to disrupt these pathways, Cleave Therapeutics aims to address both oncological and neurodegenerative diseases. Through its innovative approach to drug discovery, the company seeks to provide effective therapeutic solutions that enhance patient outcomes in the fight against cancer.

Pulmatrix is a clinical-stage biopharmaceutical company developing inhaled therapies to address serious pulmonary diseases using its patented iSPERSE technology. Its pipeline focuses on Pulmazole, an inhaled anti-fungal for allergic bronchopulmonary aspergillosis, and PUR1800, a narrow spectrum kinase inhibitor for obstructive lung diseases like asthma and COPD.

Synosia Therapeutics is a privately-owned company focused on developing and commercializing products aimed at addressing unmet medical needs in psychiatry and neurology. The company has a pipeline that includes six clinical-stage compounds, which have been acquired through strategic partnerships with major pharmaceutical firms such as Novartis, Roche, and Syngenta. Among these compounds, two are already marketed drugs that are being evaluated for new therapeutic indications to expand their application in treating neurological and psychiatric conditions, including anxiety and Parkinson's disease. In addition to its drug development efforts, Synosia Therapeutics also offers clinical development programs and research services.

Igenica, Inc. is a biotherapeutic company based in Burlingame, California, that specializes in the discovery and development of antibodies and antibody-drug conjugates (ADCs) for cancer treatment. Founded in 2008, the company focuses on creating innovative immunotherapies and functional antibodies targeting tumors. Its product pipeline includes IGN523, a humanized monoclonal antibody for various hematologic and solid tumors; IGN786, an antibody-drug conjugate; and IGN381, an immune checkpoint target that enhances the tumor microenvironment. Igenica operates with a strategic oncology research agreement with MedImmune and is supported by a leadership team experienced in antibody drug discovery and clinical development. As of 2017, Igenica operates as a subsidiary of Pierre Fabre Medicament SA, positioning it to leverage additional resources and expertise in the biotherapeutics field.

Achaogen, Inc. is a biopharmaceutical company based in South San Francisco, California, that specializes in the development and commercialization of antibacterial agents targeting multi-drug resistant (MDR) gram-negative infections. The company's primary focus is on plazomicin, which is intended for treating serious bacterial infections caused by MDR enterobacteriaceae, including carbapenem-resistant strains. Additionally, Achaogen is developing C-Scape, an orally-administered combination of clavulanate and ceftibuten aimed at addressing serious infections linked to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established collaborations with various organizations, including Thermo Fisher Scientific and Ionis Pharmaceuticals, to support its drug development efforts. The company was incorporated in 2002, but faced financial difficulties, leading to a Chapter 11 bankruptcy filing in 2019, which culminated in a liquidation plan approved in 2020. All of Achaogen's revenue has been derived from government contracts for research and development within the United States.

Pulmatrix is a clinical-stage biopharmaceutical company developing inhaled therapies to address serious pulmonary diseases using its patented iSPERSE technology. Its pipeline focuses on Pulmazole, an inhaled anti-fungal for allergic bronchopulmonary aspergillosis, and PUR1800, a narrow spectrum kinase inhibitor for obstructive lung diseases like asthma and COPD.

Envoy Therapeutics is a biotechnology company focused on drug discovery, aiming to develop new therapeutics with enhanced efficacy and reduced side effects compared to existing treatments. Utilizing its proprietary bacTRAP® technology, the company can identify proteins produced by specific cell types in vivo, eliminating the need for cell isolation. This innovative approach is particularly beneficial in complex tissues such as the brain, where numerous cell types coexist. By enabling the precise modulation of cell activity through the identification of unique protein expressions, Envoy Therapeutics is positioning itself at the forefront of advancements in targeted drug development.

Flexion Therapeutics is a biopharmaceutical company dedicated to discovering, developing, and commercializing therapies for managing musculoskeletal conditions. Its flagship product, ZILRETTA, is an intra-articular injection used for knee osteoarthritis pain management in the United States.

Pulmatrix is a clinical-stage biopharmaceutical company developing inhaled therapies to address serious pulmonary diseases using its patented iSPERSE technology. Its pipeline focuses on Pulmazole, an inhaled anti-fungal for allergic bronchopulmonary aspergillosis, and PUR1800, a narrow spectrum kinase inhibitor for obstructive lung diseases like asthma and COPD.

Igenica, Inc. is a biotherapeutic company based in Burlingame, California, that specializes in the discovery and development of antibodies and antibody-drug conjugates (ADCs) for cancer treatment. Founded in 2008, the company focuses on creating innovative immunotherapies and functional antibodies targeting tumors. Its product pipeline includes IGN523, a humanized monoclonal antibody for various hematologic and solid tumors; IGN786, an antibody-drug conjugate; and IGN381, an immune checkpoint target that enhances the tumor microenvironment. Igenica operates with a strategic oncology research agreement with MedImmune and is supported by a leadership team experienced in antibody drug discovery and clinical development. As of 2017, Igenica operates as a subsidiary of Pierre Fabre Medicament SA, positioning it to leverage additional resources and expertise in the biotherapeutics field.

Bird Rock Bio, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, with a research facility in Shanghai, China. The company specializes in the discovery and development of novel biologic therapeutics aimed at addressing immune-inflammatory conditions, including rheumatoid arthritis, metabolic diseases, fibrosis, and nonalcoholic steatohepatitis. Bird Rock Bio's technology focuses on creating highly selective monoclonal antibodies targeting specific members of the G-protein coupled receptor (GPCR) family, a class of proteins critical for therapeutic efficacy. Its lead product, RYI-008, is a potent monoclonal antibody targeting IL-6, a cytokine linked to inflammation and cancer. The company is dedicated to meeting the medical needs of patients in China while also aiming for global impact. Bird Rock Bio has a growing pipeline of therapeutic antibodies developed through proprietary technologies that ensure specificity and effectiveness in treatment.

Synosia Therapeutics is a privately-owned company focused on developing and commercializing products aimed at addressing unmet medical needs in psychiatry and neurology. The company has a pipeline that includes six clinical-stage compounds, which have been acquired through strategic partnerships with major pharmaceutical firms such as Novartis, Roche, and Syngenta. Among these compounds, two are already marketed drugs that are being evaluated for new therapeutic indications to expand their application in treating neurological and psychiatric conditions, including anxiety and Parkinson's disease. In addition to its drug development efforts, Synosia Therapeutics also offers clinical development programs and research services.

Humanigen, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, that specializes in the development of proprietary monoclonal antibodies aimed at immunotherapy and oncology treatments. The company’s leading candidate, Lenzilumab, targets granulocyte-macrophage colony-stimulating factor and is currently undergoing Phase Ib/II clinical trials for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. Additionally, Humanigen is developing Ifabotuzumab, which targets the EphA3 receptor and has completed the Phase I portion of a Phase I/II clinical trial for various hematologic malignancies. The company is also working on HGEN005, an anti-EMR1 monoclonal antibody in the pre-clinical stage for eosinophilic diseases. Humanigen has established collaborations, including a clinical partnership with Kite Pharma to study Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma and a research agreement with the Department of Defense to facilitate the development of Lenzilumab for potential emergency use in COVID-19. Formed in 2000, the company was previously known as KaloBios Pharmaceuticals and rebranded as Humanigen in 2017.

Humanigen, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, that specializes in the development of proprietary monoclonal antibodies aimed at immunotherapy and oncology treatments. The company’s leading candidate, Lenzilumab, targets granulocyte-macrophage colony-stimulating factor and is currently undergoing Phase Ib/II clinical trials for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. Additionally, Humanigen is developing Ifabotuzumab, which targets the EphA3 receptor and has completed the Phase I portion of a Phase I/II clinical trial for various hematologic malignancies. The company is also working on HGEN005, an anti-EMR1 monoclonal antibody in the pre-clinical stage for eosinophilic diseases. Humanigen has established collaborations, including a clinical partnership with Kite Pharma to study Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma and a research agreement with the Department of Defense to facilitate the development of Lenzilumab for potential emergency use in COVID-19. Formed in 2000, the company was previously known as KaloBios Pharmaceuticals and rebranded as Humanigen in 2017.

Bird Rock Bio, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, with a research facility in Shanghai, China. The company specializes in the discovery and development of novel biologic therapeutics aimed at addressing immune-inflammatory conditions, including rheumatoid arthritis, metabolic diseases, fibrosis, and nonalcoholic steatohepatitis. Bird Rock Bio's technology focuses on creating highly selective monoclonal antibodies targeting specific members of the G-protein coupled receptor (GPCR) family, a class of proteins critical for therapeutic efficacy. Its lead product, RYI-008, is a potent monoclonal antibody targeting IL-6, a cytokine linked to inflammation and cancer. The company is dedicated to meeting the medical needs of patients in China while also aiming for global impact. Bird Rock Bio has a growing pipeline of therapeutic antibodies developed through proprietary technologies that ensure specificity and effectiveness in treatment.

PhaseRx is a Seattle-based biopharmaceutical startup focused on developing intracellular enzyme replacement therapies for inherited liver diseases using its proprietary Hybrid mRNA Technology platform. This platform enables the synthesis of missing enzymes within cells, targeting three urea cycle disorders: ornithine transcarbamylase deficiency (OTCD), argininosuccinate lyase deficiency (ASL deficiency), and argininosuccinate synthetase deficiency (ASS1 deficiency). The company was founded by industry veterans and renowned academics, attracting top-tier venture capital investments.

Synosia Therapeutics is a privately-owned company focused on developing and commercializing products aimed at addressing unmet medical needs in psychiatry and neurology. The company has a pipeline that includes six clinical-stage compounds, which have been acquired through strategic partnerships with major pharmaceutical firms such as Novartis, Roche, and Syngenta. Among these compounds, two are already marketed drugs that are being evaluated for new therapeutic indications to expand their application in treating neurological and psychiatric conditions, including anxiety and Parkinson's disease. In addition to its drug development efforts, Synosia Therapeutics also offers clinical development programs and research services.

VBI Vaccines Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, with research facilities in Ottawa, Canada. It develops and sells vaccines for infectious diseases and immuno-oncology, with a focus on expanding protection in large, underserved markets. The company's enveloped virus-like particle (eVLP) platform enables the creation of vaccines that closely mimic target viruses, eliciting potent immune responses. VBI's commercial product, Sci-B-Vac, is a hepatitis B vaccine approved in Israel and 14 other countries, offering rapid onset of protection and high antibody levels. The company is also developing VBI-2601 for a functional cure of chronic hepatitis B, VBI-1901 for glioblastoma, and VBI-1501 for cytomegalovirus, among other candidates. VBI collaborates with pharmaceutical companies and research institutions, and its products are primarily distributed through direct sales to physicians and pharmacists.

Achaogen, Inc. is a biopharmaceutical company based in South San Francisco, California, that specializes in the development and commercialization of antibacterial agents targeting multi-drug resistant (MDR) gram-negative infections. The company's primary focus is on plazomicin, which is intended for treating serious bacterial infections caused by MDR enterobacteriaceae, including carbapenem-resistant strains. Additionally, Achaogen is developing C-Scape, an orally-administered combination of clavulanate and ceftibuten aimed at addressing serious infections linked to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established collaborations with various organizations, including Thermo Fisher Scientific and Ionis Pharmaceuticals, to support its drug development efforts. The company was incorporated in 2002, but faced financial difficulties, leading to a Chapter 11 bankruptcy filing in 2019, which culminated in a liquidation plan approved in 2020. All of Achaogen's revenue has been derived from government contracts for research and development within the United States.

Ikaria is an integrated critical care company that develops and delivers innovative therapeutics and interventions for critically ill patients. The company focuses on creating and commercializing advanced therapies specifically designed to address the unique and complex medical needs of this vulnerable population. By aiming to be an indispensable partner to clinicians, Ikaria seeks to enhance patient care at critical moments, ensuring that healthcare providers have access to the necessary tools and support for effective treatment.

Humanigen, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, that specializes in the development of proprietary monoclonal antibodies aimed at immunotherapy and oncology treatments. The company’s leading candidate, Lenzilumab, targets granulocyte-macrophage colony-stimulating factor and is currently undergoing Phase Ib/II clinical trials for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. Additionally, Humanigen is developing Ifabotuzumab, which targets the EphA3 receptor and has completed the Phase I portion of a Phase I/II clinical trial for various hematologic malignancies. The company is also working on HGEN005, an anti-EMR1 monoclonal antibody in the pre-clinical stage for eosinophilic diseases. Humanigen has established collaborations, including a clinical partnership with Kite Pharma to study Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma and a research agreement with the Department of Defense to facilitate the development of Lenzilumab for potential emergency use in COVID-19. Formed in 2000, the company was previously known as KaloBios Pharmaceuticals and rebranded as Humanigen in 2017.

Miikana Therapeutics is a privately held biotechnology company dedicated to the discovery and development of innovative medicines for cancer treatment. The company engages in internal drug discovery programs and also in-licenses pre-clinical and early clinical oncology drug candidates, aiming to enhance its therapeutic offerings. Through its focused approach, Miikana Therapeutics strives to advance potential treatments that address the complex challenges of cancer care.

Kalypsys specializes in pathway-based drug discovery and development services. The company conducts discovery programs across a wide range of therapeutic areas, leveraging its automated and integrated suite of technologies in biology, chemistry, and informatics. By utilizing advanced methodologies, Kalypsys aims to enhance the efficiency and effectiveness of the drug discovery process, ultimately contributing to the development of innovative therapies.

Miikana Therapeutics is a privately held biotechnology company dedicated to the discovery and development of innovative medicines for cancer treatment. The company engages in internal drug discovery programs and also in-licenses pre-clinical and early clinical oncology drug candidates, aiming to enhance its therapeutic offerings. Through its focused approach, Miikana Therapeutics strives to advance potential treatments that address the complex challenges of cancer care.